Today, Corbus Pharmaceuticals announced that the European Commission has approved orphan designation for lenabasum in the treatment of dermatomyositis...
Corbus Pharmaceuticals announced today that they will proceed with a Phase 3 clinical trial to evaluate the efficacy and...
© 2021 Myositis Support and Understanding Association (MSU). All rights reserved. | View our Privacy Policy, Terms, and Non-Discrimination policy. MSU is a charitable organization with 501(c)(3) tax-exempt status. Federal ID #47-4570748.
View COVID-19 resources and updates, and stay tuned to your state, local, and federal health agencies, along with the CDC.
<
